Blueberry Therapeutics Limited would like to announce that it has completed a £3.6m extension to the previously successful Series B Fundraising of £10.8m. This investment is from a Japanese investor, Medical Incubator Japan (MIJ) and a private syndicate of US Board Certified Dermatologists led by Dr Omar Ibrahimi of Stamford, CT. Blueberry Therapeutics is a dermatology-focused drug discovery and development company focused on developing innovative nanomedicines for difficult to treat diseases of the skin and nail, with a lead candidate in Phase II development.